Laurus Labs Ltd.
NSE: LAURUSLABSLaurus Labs Ltd.: A 30-second snapshot
Laurus Labs trades at Rs 1,816.2, up 99.98% over the past 12 months and 54.38% over the last 3 months, sitting just 0.57% below its 52-week high with an RSI of 81.83. Q1 FY27 results (quarter ended June 30, 2026) reported record revenue and profit with EPS more than doubling year-over-year and consolidated net profit of Rs 3.68 billion, while the stock trades at a trailing PE of 89.42x versus a peer range of 28.9x-74.58x.
P/E
89.4
Forward P/E
63.3
ROE
—
Debt / Equity
46.37
Profit Margin
+15.0%
Div. Yield
+0.1%
5Y ROE > 15%
2/5
5Y FCF > 0
2/5
Quality
50/100
News
8 headlines · 3 positive · 1 negative
Laurus Labs proceeds with court-directed steps towards business restructuring - Business Upturn
Business Upturn
Laurus Labs Limited Reports Earnings Results for the First Quarter Ended June 30, 2026 - marketscreener.com
marketscreener.com
LAURUSLABS: Q1 FY27 delivered record revenue and profit growth, led by CDMO and generics momentum - TradingView
TradingView
LAURUSLABS: Strong revenue and profit growth, with EPS more than doubling year-over-year - TradingView
TradingView
Laurus Labs June-Quarter Consol Net Profit 3.68 Billion Rupees - TradingView
TradingView
Recent context
- ·Q1 FY27 (quarter ended June 30, 2026) results reported record revenue and profit, consolidated net profit of Rs 3.68 billion and EPS more than doubling year-over-year (TradingView, 2026-07-24).
- ·A separate July 25, 2026 report (Business Upturn) noted the company proceeds with court-directed steps toward business restructuring, tagged negative in sentiment; the tracked headline set gives limited additional detail on scope.
- ·Mean analyst rating of 2.57 across 14 analysts (1-5 scale, lower = more constructive).
Strengths
- +Composite quality score of 57 ranks 1st of 6 in the reported pharma peer set (Sun Pharma 56, Apollo Hospitals 44, Max Healthcare 37, Cipla 28, Dr Reddy's 4).
- +5-year revenue growth of 29.1% and 5-year earnings growth of 125.2%, with Q1 FY27 reported as record revenue and profit, consolidated net profit of Rs 3.68 billion and EPS more than doubling year-over-year.
- +Price trades above both its 50-day (Rs 1,493.93) and 200-day (Rs 1,159.63) moving averages and is within 0.57% of its 52-week high.
- +News flow over the 8 tracked items skews positive (3 positive, 4 neutral, 1 negative), concentrated around the Q1 FY27 earnings release.
Weaknesses
- −Free cash flow was positive in only 2 of the tracked years and the consistency score is 19, alongside a debt trend recorded as rising (debt-to-equity of 0.46x) — profitability growth has not been consistently mirrored in free cash flow generation.
- −Trailing PE of 89.42x (forward 63.34x) is the richest among the 6 reported pharma peers (28.9x-74.58x), ranking last (6th of 6) on PE.
- −RSI of 81.83 signals overbought conditions; price is roughly 21.6% above the 50-DMA and 56.6% above the 200-DMA after a 99.98% 12-month advance.
- −ROE exceeded 15% in only 2 of the tracked years, and current-period ROE is not reported in the latest fundamental snapshot.
Open questions
- ?Does the gap between 5-year earnings growth of 125.2% and free cash flow positive in only 2 of the tracked years reflect timing differences in working capital, or a more structural cash-conversion pattern?
- ?What is the scope and expected timeline of the court-directed business restructuring referenced in the July 25 report, and how might it relate to the CDMO and generics segments driving the Q1 FY27 results?
- ?How does the current trailing PE of 89.42x, the highest among reported peers, compare with the company's own historical PE range, and what growth trajectory would be consistent with it?
- ?With RSI at 81.83 and price near its 52-week high, how has the stock historically behaved around the nearest support levels (Rs 1,448.2 / Rs 1,342.9) relative to its 50- and 200-day averages?
Peer comparison: Pharma
Ranks 1 of 6 on quality| Symbol | Name | P/E | ROE | Quality |
|---|---|---|---|---|
| LAURUSLABS | Laurus Labs Ltd.You're viewing | 89.4 | — | 57 |
| Industry avg | across 5 peers | 49.4 | +14.8% | 34 |
| SUNPHARMA | Sun Pharmaceutical Industries Ltd. | 41.6 | +14.7% | 56 |
| APOLLOHOSP | Apollo Hospitals Enterprise Ltd. | 66.4 | +21.5% | 44 |
| MAXHEALTH | Max Healthcare Institute Ltd. | 74.6 | +14.3% | 37 |
| CIPLA | Cipla Ltd. | 35.4 | — | 28 |
| DRREDDY | Dr. Reddy's Laboratories Ltd. | 28.9 | +8.8% | 4 |
Technical state
Current price
₹1,816.20
SMA 50
₹1,493.93
SMA 200
₹1,159.63
RSI (14)
81.8 (overbought)
From 52w high
-0.6%
1Y return
+100.0%
3M return
+54.4%
50-DMA
Above
200-DMA
Above
Algorithmic support levels
Risk flags
- highFree cash flow was positive in only 2 of the tracked years and the earnings-consistency score is 19 (low), while the debt trend is recorded as rising (debt-to-equity of 0.46x, i.e. 46.369 on Yahoo's percent-scaled metric) — reported 5-year earnings growth of 125.2% has not been consistently mirrored in free cash flow generation.
- mediumRSI of 81.83 sits in overbought territory; price is roughly 21.6% above the 50-DMA (Rs 1,493.93) and 56.6% above the 200-DMA (Rs 1,159.63) after a 99.98% advance over 12 months and 54.38% over 3 months, with the stock only 0.57% below its 52-week high.
- mediumTrailing PE of 89.42x (forward PE 63.34x) is the richest among the 6 reported pharma peers (range 28.9x-74.58x: Dr Reddy's, Cipla, Sun Pharma, Apollo Hospitals, Max Healthcare), ranking last (6th of 6) on the PE dimension even though it ranks 1st of 6 on the composite quality score.
- lowA July 25, 2026 report (Business Upturn) noted the company proceeds with court-directed steps toward business restructuring, tagged negative in sentiment, alongside otherwise positive Q1 FY27 earnings coverage; the tracked headline set does not provide further detail on scope or timeline.
Cross-section contradictions
- 5-year earnings growth of 125.2% and revenue growth of 29.1% contrast with free cash flow positive in only 2 of the tracked years and a consistency score of 19, leaving it unclear how much of reported profit growth has converted into free cash flow.
- Price has gained 99.98% over 12 months and trades just 0.57% below its 52-week high, while historical profitability metrics (ROE above 15% in only 2 of the tracked years; consistency score of 19) point to a record of uneven historical returns relative to the scale of the recent price move.
For informational purposes only. Not investment advice. VivaTrades is not a SEBI-registered Investment Adviser or Research Analyst. Market data sourced from public feeds; consult a registered adviser before any investment decision.
Fundamentals & technicals: refreshed 11 Aug 2026 · refreshed daily at 01:00 IST
AI synthesis (narrative, snapshot, strengths/weaknesses, peer ranking): generated 1 Aug 2026 · rotates through NIFTY 500 every ~5 days